References
- Braga F, Infusino I, Dolci A, Panteghini M. 2013. Biological variation of free light chains in serum. Clin Chim Acta. 415:10–11. doi: 10.1016/j.cca.2012.09.008
- Díaz-Garzón J, Fernández-Calle P, Minchinela J, Aarsand AK, Bartlett WA, Aslan B, Boned B, Braga F, Carobene A, Coskun A, et al. 2019. biological variation data for lipid cardiovascular risk assessment biomarkers. A systematic review applying the biological variation data critical appraisal checklist (BIVAC). Clin Chim Acta. 495:467–475. doi: 10.1016/j.cca.2019.05.013
- Finlay J, Wu AHB. 2014. Biological variation of immunoglobulin heavy-light chain pairs in serum. Clin Chim Acta. 436:68–71. doi: 10.1016/j.cca.2014.05.002
- Fraser CG. 2001. Biological variation: from principles to practice. Washington DC:AACC Press,
- Kazandiian D. 2016. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol. 43:676–681.
- Niewiesk S. 2014. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 5:446. doi: 10.3389/fimmu.2014.00446
- Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Oskarsson JP, Petursdottir I, et al. 2021. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer. J. 11:1–13.
- Smith A, Wu AHB. 2018. Analytical and clinical concordance of free light chain assays. Pract Lab Med. 13:e00112. doi: 10.1016/j.plabm.2018.e00112
- Wu AHB. 2021. Kappa/lambda ratio for early detection of multiple myeloma relapse using the reference change value from biological variation studies. J Appl Lab Med. 6(6):1683–1687. doi: 10.1093/jalm/jfab093